An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Subscribe To Our Newsletter & Stay Updated
